History of atopy or severe anaphylactic reaction to a variety of allergens. May be systemically absorbed & adverse reactions seen w/ oral β-blockers may occur. Reports of resp & cardiac reactions including death due to bronchospasm in patients w/ asthma, & rarely, death associated w/ cardiac failure; choroidal detachment w/ aq suppressant therapy (eg, acetazolamide) after filtration procedures; bacterial keratitis. β-adrenergic blockade has been reported to potentiate muscle weakness consistent w/ certain myasthenic symptoms eg, diplopia, ptosis, & generalized weakness. Development of intercurrent ocular condition eg, trauma, ocular surgery or infection. Patients w/ sick sinus syndrome, Prinzmetal's angina, untreated phaechromocytoma, metabolic acidosis, HTN, & diabetes. Adequately control cardiac failure prior to therapy. Watch for signs of cardiac failure in patients w/ history of severe cardiac disease. Remove soft contact lenses prior to instillation & do not re-insert earlier than 15 min after use. Avoid allowing of container tip to contact the eye-surrounding structures. Prolonged therapy. Not to be concurrently used w/ another topical ophth β-adrenergic blocking agents. Use w/ miotic & not alone when used to reduce IOP in angle-closure glaucoma. At least 10-min interval between each application is recommended when additional ophth medication is used. Dizziness, fatigue, transient ocular irritation, blurred vision & lacrimation may occasionally occur & may affect ability to drive & use machines. Not to be used during pregnancy. Not recommended during lactation. Not recommended in childn <12 yr.
Sign Out
Continue with Google
Sign up with email
Already a member?
Sign in
